Schermer M H N
Department of Medical Ethics and Philosophy of Medicine, Erasmus Medical Center, University of Rotterdam, Room AE 340, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Med Health Care Philos. 2007 Jun;10(2):119-28. doi: 10.1007/s11019-007-9059-1. Epub 2007 May 8.
Aldous Huxley's Brave New World is a famous dystopia, frequently called upon in public discussions about new biotechnology. It is less well known that 30 years later Huxley also wrote a utopian novel, called Island. This paper will discuss both novels focussing especially on the role of psychopharmacological substances. If we see fiction as a way of imagining what the world could look like, then what can we learn from Huxley's novels about psychopharmacology and how does that relate to the discussion in the ethical and philosophical literature on this subject? The paper argues that in the current ethical discussion the dystopian vision on psychopharmacology is dominant, but that a comparison between Brave New World and Island shows that a more utopian view is possible as well. This is illustrated by a discussion of the issue of psychopharmacology and authenticity. The second part of the paper draws some further conclusions for the ethical debate on psychopharmacology and human enhancement, by comparing the novels not only with each other, but also with our present reality. It is claimed that the debate should not get stuck in an opposition of dystopian and utopian views, but should address important issues that demand attention in our real world: those of evaluation and governance of enhancing psychopharmacological substances in democratic, pluralistic societies.
奥尔德斯·赫胥黎的《美丽新世界》是一部著名的反乌托邦小说,在关于新生物技术的公开讨论中经常被提及。鲜为人知的是,30年后赫胥黎还写了一部乌托邦小说,名为《岛》。本文将讨论这两部小说,特别关注精神药物的作用。如果我们将小说视为一种想象世界可能模样的方式,那么我们能从赫胥黎的小说中学到关于精神药理学的哪些知识,以及这与该主题的伦理和哲学文献中的讨论有何关联?本文认为,在当前的伦理讨论中,对精神药理学的反乌托邦观点占主导地位,但《美丽新世界》和《岛》的比较表明,也可能存在更乌托邦的观点。这通过对精神药理学与真实性问题的讨论得以说明。本文的第二部分通过将这两部小说相互比较,以及与我们当前的现实进行比较,为精神药理学和人类增强的伦理辩论得出了一些进一步的结论。有人认为,这场辩论不应陷入反乌托邦和乌托邦观点的对立之中,而应关注我们现实世界中需要关注的重要问题:即在民主、多元社会中对增强型精神药物的评估和管理问题。